Apogee Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
The phase II APEX Part A study showed zumilokibart maintained and deepened efficacy in atopic dermatitis over 52 weeks with both three- and six-month dosing, offering strong lesion and itch control and a favorable safety profile. Reduced injection frequency addresses key patient needs and positions the drug as a potential first-line therapy.
-
Upcoming maintenance data aims to validate quarterly and semi-annual dosing for atopic dermatitis, with phase 3 trials launching this year and full funding secured through 2028. Market research supports strong uptake potential, and expansion into asthma, EoE, and combination therapies is planned.
-
Recent data show rapid itch relief and durable efficacy in atopic dermatitis and asthma, with a focus on extending dosing intervals and maintaining a strong safety profile. Plans include a 2029 launch, label expansion, and development of combination therapies to address broader inflammatory conditions.
-
Interim phase I-B data for zumilokibart in asthma showed robust, durable FeNO suppression and a favorable safety profile, supporting dosing every three or six months. The results align with standard-of-care agents and position the therapy for late-stage development in major I&I markets.
Fiscal Year 2025
-
Multiple pivotal clinical readouts for 777 in AD and asthma are expected in 2026, with a focus on infrequent dosing, rapid itch relief, and strong efficacy. Market research and commercial trends support high adoption potential, while combination strategies and expansion into asthma and COPD are planned.
-
Major clinical milestones are expected next year, including four readouts for atopic dermatitis and asthma, with a focus on combination therapies targeting IL-13 and OX40L. The strategy emphasizes both depth and breadth of efficacy, aiming for improved outcomes over current standards like Dupixent.
-
Upcoming data for APG777 in asthma and atopic dermatitis could set new efficacy and durability standards, with phase 3 trials and a 2029 launch targeted. Market research shows strong physician preference, and a robust cash position supports ongoing and future studies.
-
Multiple late-stage clinical readouts are expected in the next year, including maintenance dosing and head-to-head data versus Dupixent. The pipeline is positioned for frontline and second-line atopic dermatitis use, with expansion into asthma and respiratory indications, supported by strong financial resources.
-
The team highlighted strong phase II data for their lead IL-13 antibody in atopic dermatitis, robust market growth, and a strategy focused on long-acting, co-formulated combinations. Key catalysts are expected in 2026, with phase III trials and expanded indications on the horizon.
-
The team presented new phase II data for their lead AD therapy, highlighting strong efficacy, early itch relief, and a favorable safety profile. With a robust cash position and a focus on quarterly dosing, they plan key data readouts in 2026 and a potential AD launch in 2029.
-
Phase II APEX Part A data for APG-777 in atopic dermatitis showed over 70% EASI reduction and 66.9% EASI-75 response at week 16, with rapid, deep itch relief and a favorable safety profile. Higher exposures correlated with greater efficacy, and future studies will test even higher doses and combination therapy.
-
The team is advancing a long-acting IL-13 antibody for atopic dermatitis, targeting a mid-year phase II readout and aiming for superior dosing convenience. Combination therapies and respiratory franchise expansion are key strategic priorities, with strong market and payer interest in improved efficacy and adherence.
-
Three drugs are advancing across four indications, with Evexetide in phase 3 for PBH and AMX-35 showing promising results in Wolfram syndrome. Evexetide’s phase 2B data showed significant reductions in severe hypoglycemic events, and top-line pivotal data is expected in H1 2026.
-
The company is advancing APG777, an optimized anti-IL-13 antibody, in phase 2 for atopic dermatitis with transformative dosing and expansion into asthma and EOE. Combination therapies, including APG279, are prioritized, supported by strong financials and robust trial design.
-
The session highlighted a robust pipeline of long-acting antibody therapies for atopic dermatitis and related I&I conditions, with key data expected mid-year. Strong clinical differentiation, flexible dosing, and a solid financial position support ambitions for market leadership and significant commercial impact.
-
Interim phase I results for APG990 show a favorable safety profile and a 60-day half-life, supporting the potential for every three- or six-month dosing. The APG279 combination aims for best-in-class efficacy in atopic dermatitis, with a head-to-head trial against Dupixent planned for later this year and initial data expected in 2026.
-
The team outlined a strategy focused on best-in-class antibody engineering for type 2 inflammation, emphasizing co-formulation over bispecifics for longer dosing intervals and lower costs. Rigorous clinical trial design and payer research support strong market access, with multiple pipeline catalysts expected this year.
Fiscal Year 2024
-
Lead antibody APG777 is advancing rapidly, with phase 2 data now expected mid-2025 and strong potential for best-in-class dosing and efficacy in atopic dermatitis. Combination therapies targeting broader inflammatory pathways are progressing, with multiple clinical milestones anticipated in 2025.
-
Management outlined a strategy focused on APG-777 for atopic dermatitis, integrating efficient trial designs and prioritizing combination therapies to enhance efficacy and safety. The pipeline includes TSLP and OX40L, with flexible co-formulation approaches and a focus on biomarker-driven patient selection.
-
The team is advancing a pipeline of optimized antibodies for major I&I markets, focusing on less frequent dosing and combination strategies. Key programs are progressing through clinical trials, with significant data readouts and commercial updates expected at the December R&D day.
-
The event highlighted a strategy centered on optimized antibodies and innovative combinations for inflammatory diseases, with APG777 and APG990 leading development in atopic dermatitis and respiratory indications. Market potential is significant, and upcoming clinical milestones and an R&D Day were announced.
-
The team highlighted progress on a pipeline of optimized antibodies for inflammatory diseases, with APG-777 showing strong phase I data and a robust phase II design targeting atopic dermatitis. Combination strategies and less frequent dosing regimens are positioned as key differentiators, with major updates expected at an upcoming R&D Day.
-
The company is advancing best-in-class monotherapies and combinations for major I&I markets, with a lead program targeting extended dosing in atopic dermatitis and a robust IP position. Integrated clinical trials, early maintenance data, and a focus on combination therapies aim to accelerate development and address unmet needs.
-
The team is advancing optimized antibodies for major inflammatory diseases, prioritizing combinations like OX40L and IL-13 to achieve broad efficacy and safety. Integrated clinical trials and disciplined capital deployment support rapid development, with new targets and updates expected at the R&D Day.